PT  - JOURNAL ARTICLE
AU  - Inés Figueroa, María
AU  - Sued, Omar
AU  - Cesar, Carina
AU  - Patterson, Patricia
AU  - Yamamoto, Cleyton
AU  - Fink, Valeria
AU  - Luna, Norma
AU  - Camiro-Zúñiga, Antonio
AU  - Gun, Ana
AU  - Cahn, Pedro
TI  - Dual therapy with Atazanavir/ritonavir plus Raltegravir versus triple therapy with Atazanavir/ritonavir plus Tenofovir-Emtricitabine after failure to an NNRTI regimen: 48-week results of the randomized pilot study ARTE trial
AID  - 10.1101/2022.07.08.22277426
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.08.22277426
4099  - http://medrxiv.org/content/early/2022/07/09/2022.07.08.22277426.short
4100  - http://medrxiv.org/content/early/2022/07/09/2022.07.08.22277426.full
AB  - Background Dual therapy has emerged as a novel concept for HIV treatment. The ARTE study was aimed at comparing a nucleoside-sparing dual regimen consisting of ATV/r + RAL (DT) vs standard therapy of ATV/r + TDF/FTC (TT) among individuals failing first NNRTI-containing treatment.Methods Randomized multicenter open-label pilot study. Primary outcome: proportion of subjects with plasma HIV-1 RNA below the limit of detection (<50 copies/mL) at 48 weeks (W48). Secondary outcomes: proportion of discontinuation due to adverse events (AEs), time until viral suppression, time until loss of virological response, development of integrase resistance mutations, and absolute change in CD4 counts. The primary outcome was analyzed using the FDA snapshot analysis.Results Out of 57 participants screened, 34 were randomized to receive: DT (n: 18) or TT (n: 16). At W48, virological response was achieved in 67% (n: 12/18) of participants receiving DT and 88% (n: 14/16) receiving TT by FDA snapshot analysis (p = NS) and, 73% and 93% by per-protocol analysis (p = NS). CD4 cell count median change from baseline to W48 was +119 and + 52 cell/μL in DT and TT, respectively. Four participants receiving DT and one TT presented virological failure at W48, with low pVL. One participant developed an integrase resistance mutation (155H) and suppressed later on TT.Conclusion ATV/r+RAL as second-line therapy showed a trend to more frequent virological failure, compared to TT, although the study was unpowered to prove this difference. No major differences were seen in tolerance or toxicity.This study is registered with ClinicalTrials.gov, Number: NCT01829802Competing Interest StatementThe authors participated in the ARTE study, where Fundacion Huesped was the sponsor of the study, and MSD provided funds to carry out the study procedures and raltegravir.Clinical TrialNCT01829802Funding StatementThis study was funded by Merck Co. through investigator-initiated research granted to Fundacion Huesped.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ARTE study was approved by the Comite de Bioetica de Fundacion Huesped FWA IORG0001557, IRB00002014. Participants provided written informed consent before any study procedure.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors